@article{StoevesandtHofmannHainetal.2013,
  author    = {Stoevesandt, Johanna and Hofmann, Bernd and Hain, Johannes and Kerstan, Andreas and Trautmann, Axel},
  title     = {Single venom-based immunotherapy effectively protects patients with double positive tests to honey bee and Vespula venom},
  series = {Allergy, Asthma \& Clinical Immunology},
  journal   = {Allergy, Asthma \& Clinical Immunology},
  doi       = {10.1186/1710-1492-9-33},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-96808},
  year      = {2013},
  abstract  = {Background Referring to individuals with reactivity to honey bee and Vespula venom in diagnostic tests, the umbrella terms "double sensitization" or "double positivity" cover patients with true clinical double allergy and those allergic to a single venom with asymptomatic sensitization to the other. There is no international consensus on whether immunotherapy regimens should generally include both venoms in double sensitized patients. Objective We investigated the long-term outcome of single venom-based immunotherapy with regard to potential risk factors for treatment failure and specifically compared the risk of relapse in mono sensitized and double sensitized patients. Methods Re-sting data were obtained from 635 patients who had completed at least 3 years of immunotherapy between 1988 and 2008. The adequate venom for immunotherapy was selected using an algorithm based on clinical details and the results of diagnostic tests. Results Of 635 patients, 351 (55.3\%) were double sensitized to both venoms. The overall re-exposure rate to Hymenoptera stings during and after immunotherapy was 62.4\%; the relapse rate was 7.1\% (6.0\% in mono sensitized, 7.8\% in double sensitized patients). Recurring anaphylaxis was statistically less severe than the index sting reaction (P = 0.004). Double sensitization was not significantly related to relapsing anaphylaxis (P = 0.56), but there was a tendency towards an increased risk of relapse in a subgroup of patients with equal reactivity to both venoms in diagnostic tests (P = 0.15). Conclusions Single venom-based immunotherapy over 3 to 5 years effectively and long-lastingly protects the vast majority of both mono sensitized and double sensitized Hymenoptera venom allergic patients. Double venom immunotherapy is indicated in clinically double allergic patients reporting systemic reactions to stings of both Hymenoptera and in those with equal reactivity to both venoms in diagnostic tests who have not reliably identified the culprit stinging insect.},
  language  = {en}
}
@phdthesis{Hendriksma2011,
  author    = {Hendriksma, Harmen P.},
  title     = {Non-target effects of a multiple insect resistant Bt-maize on the honey bee (Apis mellifera L.)},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-70304},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2011},
  abstract  = {Neue methodische Entwicklungen zur Untersuchung der Ursachen des weltweit beobachteten Bienensterbens sind n{\"o}tig, um die lebenswichtige {\"O}kosystemdienstleistung der Best{\"a}ubung zu gew{\"a}hrleisten. Die {\"o}kologisch und wirtschaftlich bedeutsame Honigbiene (Apis mellifera) ist ein wichtiger Nichtziel-Organismus im Zulassungsverfahren f{\"u}r gentechnisch ver{\"a}nderte Pflanzen. Bisher sind vor allem Methoden zur Testung erwachsener Bienen unter Laborbedingungen verwendet worden, aber f{\"u}r eine Risikobewertung mit Hilfe von standardisierten Bienenkolonien oder in vitro gez{\"u}chteten Honigbienenlarven sind keine robusten Methoden oder standardisierte Protokolle vorhanden. In dieser Arbeit wurde eine Vielzahl an neuen methodischen Ans{\"a}tzen f{\"u}r die Biosicherheitsforschung entwickelt: eine Mortalit{\"a}ts-Falle (Kapitel II), ein "Full-Life-Cycle" Test (III), eine robuste in vitro Aufzucht-Methodik (IV), ein standardisierter in vitro Test f{\"u}r Bt-Pollen (V), eine gemischte Toxizit{\"a}tspr{\"u}fung f{\"u}r transgene Reinproteine (VI) und eine {\"U}berpr{\"u}fung der Darmmikroflora sowie der Pollenverdauungrate (VII). Die Ergebnisse dieser Studien zeigten keine nachteiligen Wirkungen von Bt-Maispollen oder Bt-Reinproteinen im "Worst-Case" Szenario auf Honigbienen. In Anbetracht der Datenlage ist eine Sch{\"a}digung der Honigbiene durch den getesteten Bt-Mais Mon89034xMon88017 unwahrscheinlich. Die Anwendung der Untersuchungsmethoden in zuk{\"u}nftigen Biosicherheitsstudien f{\"u}r transgene Pflanzen wird empfohlen.},
  subject      = {Biene},
  language  = {en}
}